drugset / Trial / NCT00573144

Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction

NCT00573144

Phase 2 Completed 59 enrolled Mayo Clinic
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine the efficacy of intravenous human beta natriuretic peptide (BNP, Nesiritide) as compared to placebo to prevent adverse post acute myocardial infarction left ventricular remodeling.

Timeline

Start
2006-09
Primary completion
2012-11
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nesiritide Protein / enzyme biologic 0.006 ug/kg Intravenous